Cargando…

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis

INTRODUCTION: Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct pathophysiological mechanisms, clinical features and treatment responses. Rituximab is a licensed therapy for granulomatosis with polyang...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teixeira, Vítor, Mohammad, Aladdin J, Jones, Rachel B, Smith, Rona, Jayne, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Vasculitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560673/ https://www.ncbi.nlm.nih.gov/pubmed/31245051 http://dx.doi.org/10.1136/rmdopen-2019-000905

Ejemplares similares

Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis
por: Merkel, Peter A., et al.
Publicado: (2021)

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
por: Bettiol, Alessandra, et al.
Publicado: (2021)

Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis
por: Brogan, Paul, et al.
Publicado: (2021)

Score to assess the probability of relapse in granulomatosis with polyangiitis and microscopic polyangiitis
por: Samson, Maxime, et al.
Publicado: (2023)

Eosinophilic granulomatosis polyangiitis (EGPA) complicated with periaortitis, precipitating role of dupilumab? A case report a review of the literature
por: Kai, Martine, et al.
Publicado: (2023)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
por: Sanchez-Alamo, Beatriz, et al.
Publicado: (2023)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Schirmer, Jan Henrik, et al.
Publicado: (2023)

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease
por: Kubo, Satoshi, et al.
Publicado: (2022)

Proteinase 3 promotes formation of multinucleated giant cells and granuloma-like structures in patients with granulomatosis with polyangiitis
por: Henderson, Scott R, et al.
Publicado: (2023)

Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry
por: Puéchal, Xavier, et al.
Publicado: (2022)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case–control study
por: Turkiewicz, Aleksandra, et al.
Publicado: (2020)

Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
por: Heijl, Caroline, et al.
Publicado: (2017)

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study
por: Jayne, David, et al.
Publicado: (2019)

Eosinophilic granulomatosis with polyangiitis with severe pulmonary hemorrhage treated with rituximab
por: Baikunje, S., et al.
Publicado: (2016)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
por: Pradhan, Ravi Ranjan, et al.
Publicado: (2019)

Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab
por: Geetha, Duvuru, et al.
Publicado: (2014)

Risk factors for serious infections in ANCA-associated vasculitis
por: Odler, Balazs, et al.
Publicado: (2023)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study
por: Rutherford, Matthew A., et al.
Publicado: (2021)

Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
por: Thiel, Jens, et al.
Publicado: (2013)

Eosinophilic Granulomatosis with Polyangiitis
por: Shukla, Ratnakar, et al.
Publicado: (2022)

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
por: Cid, Maria C, et al.
Publicado: (2022)

Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement
por: Afiari, Agura, et al.
Publicado: (2020)

Rituximab and dupilumab improve eosinophilic granulomatosis with polyangiitis with multiple pulmonary thrombi
por: Adachi, Sei, et al.
Publicado: (2022)

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
por: Koga, Yasuhiko, et al.
Publicado: (2022)

Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool
por: Sebastian, Alwin, et al.
Publicado: (2020)

COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?
por: Özdemir, Bahar, et al.
Publicado: (2021)

Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Shah, Shivani, et al.
Publicado: (2015)

Eosinophilic Granulomatosis with Polyangiitis: An Overview
por: Gioffredi, Andrea, et al.
Publicado: (2014)

Prevasculitic Eosinophilic Granulomatosis With Polyangiitis
por: Burtson, Kathryn M, et al.
Publicado: (2021)

Eosinophilic Variant of Granulomatosis With Polyangiitis
por: Fernandes, Rui L, et al.
Publicado: (2023)

Correction to: COVID-19 and eosinophilic granulomatosis with polyangiitis or COVID-19 mimicking eosinophilic granulomatosis with polyangiitis?
por: Özdemir, Bahar, et al.
Publicado: (2021)

Eosinophilic Cholecystitis Associated with Eosinophilic Granulomatosis with Polyangiitis
por: Ito, Hiroyuki, et al.
Publicado: (2020)

Renal Involvement in Eosinophilic Granulomatosis With Polyangiitis
por: Doreille, Alice, et al.
Publicado: (2021)

A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis
por: Quan, Michele V., et al.
Publicado: (2018)

Eosinophilic granulomatosis with polyangiitis after treatment with dupilumab
por: Yamazaki, Kai, et al.
Publicado: (2022)

PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis
por: Lester, Susan, et al.
Publicado: (2016)

Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis—a meta-analysis
por: Kuzuya, Kentaro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ij8rgqotone7k0jmkk7336lmuc